Smith Group Asset Management LLC Has $25.81 Million Stock Position in Medpace Holdings, Inc. $MEDP

Smith Group Asset Management LLC boosted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.2% during the second quarter, Holdings Channel reports. The institutional investor owned 82,223 shares of the company’s stock after acquiring an additional 2,529 shares during the quarter. Medpace comprises about 1.7% of Smith Group Asset Management LLC’s investment portfolio, making the stock its 28th biggest position. Smith Group Asset Management LLC’s holdings in Medpace were worth $25,807,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of MEDP. Mawer Investment Management Ltd. bought a new position in shares of Medpace during the first quarter valued at $212,131,000. Vulcan Value Partners LLC lifted its holdings in shares of Medpace by 221.6% during the first quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company’s stock valued at $99,159,000 after acquiring an additional 224,578 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Medpace by 675.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company’s stock valued at $37,009,000 after acquiring an additional 105,807 shares during the period. Invesco Ltd. lifted its holdings in shares of Medpace by 9.4% during the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock valued at $361,596,000 after acquiring an additional 102,015 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Medpace by 36.0% during the first quarter. Northern Trust Corp now owns 337,489 shares of the company’s stock valued at $102,830,000 after acquiring an additional 89,347 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insider Activity at Medpace

In related news, VP Susan E. Burwig sold 10,000 shares of the firm’s stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the sale, the vice president directly owned 57,500 shares in the company, valued at $27,600,000. This trade represents a 14.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the firm’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the sale, the general counsel owned 10,343 shares in the company, valued at approximately $4,654,350. The trade was a 22.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 107,465 shares of company stock valued at $49,720,216. Insiders own 20.30% of the company’s stock.

Medpace Price Performance

Shares of MEDP stock opened at $596.61 on Friday. The stock has a market cap of $16.76 billion, a PE ratio of 41.72, a price-to-earnings-growth ratio of 3.39 and a beta of 1.40. The stock has a 50-day moving average of $500.19 and a 200-day moving average of $389.01. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $625.00.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 81.62% and a net margin of 18.36%.The company had revenue of $659.90 million during the quarter, compared to analysts’ expectations of $640.49 million. During the same period in the prior year, the business posted $3.01 EPS. Medpace’s revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on MEDP shares. William Blair reissued a “market perform” rating on shares of Medpace in a report on Wednesday, July 23rd. UBS Group cut Medpace from a “neutral” rating to a “sell” rating and lifted their price target for the company from $300.00 to $305.00 in a report on Tuesday, July 29th. Truist Financial lifted their price target on Medpace from $298.00 to $436.00 and gave the company a “hold” rating in a report on Wednesday, July 23rd. Cowen cut Medpace from a “buy” rating to a “sell” rating in a report on Wednesday, July 23rd. Finally, Zacks Research cut Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, September 22nd. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $430.60.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.